Published in Nat Rev Rheumatol on February 21, 2012
Vitamin D deficiency, interleukin 17, and vascular function in rheumatoid arthritis. J Rheumatol (2013) 1.44
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) (2014) 1.34
The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis. Arthritis Res Ther (2013) 1.01
Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm (2012) 0.99
Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells. Mediators Inflamm (2012) 0.93
Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediators Inflamm (2012) 0.91
SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther (2013) 0.88
SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients. PLoS One (2013) 0.88
Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. Mediators Inflamm (2013) 0.84
Association of Cardiovascular Risk Factors with Carotid Intima Media Thickness in Patients with Rheumatoid Arthritis with Low Disease Activity Compared to Controls: A Cross-Sectional Study. PLoS One (2015) 0.83
Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther (2012) 0.79
Subclinical atherosclerosis in patients with rheumatoid arthritis by utilizing carotid intima-media thickness as a surrogate marker. Indian J Med Res (2014) 0.78
Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci (2012) 0.78
Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Res Ther (2015) 0.77
Can the ankle brachial pressure index (ABPI) and carotis intima media thickness (CIMT) be new early stage markers of subclinical atherosclerosis in patients with rheumatoid arthritis? Wien Klin Wochenschr (2015) 0.76
Atherosclerosis in rheumatoid arthritis. Mediators Inflamm (2012) 0.75
Carotid artery stiffness in Behçet's disease. Eur J Rheumatol (2017) 0.75
Increased carotid intima-media thickness in rheumatoid arthritis: an update meta-analysis. Clin Rheumatol (2015) 0.75
Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis. Arthritis Res Ther (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J (2006) 17.53
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
The pathogenesis of atherosclerosis--an update. N Engl J Med (1986) 14.59
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 11.50
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation (2006) 10.05
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA (2010) 8.90
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr (2008) 7.91
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84
Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med (1986) 6.05
Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation (2007) 5.87
Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation (1986) 5.82
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol (2010) 5.79
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36
Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol (1995) 5.26
Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J (2010) 5.02
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 4.58
Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension (1999) 4.56
Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol (2003) 3.87
The search for new risk factors for coronary heart disease: occupational therapy for epidemiologists? Int J Epidemiol (2002) 3.74
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J (2003) 3.73
Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol (1994) 3.71
High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis (2004) 3.55
Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J Hypertens (2010) 3.39
Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J (2010) 3.22
Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum (2005) 3.17
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 2.77
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation (2006) 2.70
Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) (2009) 2.67
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 2.45
Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J (2002) 2.38
Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum (2004) 2.32
Endothelial function predicts progression of carotid intima-media thickness. Circulation (2009) 2.30
Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum (2003) 2.29
Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum (2008) 2.21
The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. Arch Intern Med (2001) 2.15
Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke (2002) 2.10
Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens (2005) 2.09
Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation (2005) 2.03
Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci (2006) 1.95
The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis (2006) 1.83
Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum (2008) 1.78
Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum (2007) 1.78
Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol (1991) 1.76
Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) (2003) 1.75
Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation (1993) 1.74
Elevated serum C-reactive protein levels and early arterial changes in healthy children. Arterioscler Thromb Vasc Biol (2002) 1.71
Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med (2008) 1.70
Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) (2005) 1.65
Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62
Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens (2009) 1.62
Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke (1997) 1.61
Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil (2011) 1.55
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis (2010) 1.55
Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis (2004) 1.53
Mechanical principles in arterial disease. Hypertension (1995) 1.43
Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler Thromb Vasc Biol (2002) 1.40
Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther (2007) 1.37
Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36
HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med (2003) 1.36
Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis (2008) 1.34
Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Res Ther (2009) 1.33
Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med (2008) 1.33
Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J (2010) 1.32
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum (2007) 1.31
A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol (2001) 1.31
A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods. J Hypertens (2008) 1.30
Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol (2009) 1.30
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29
Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device. J Hypertens (2004) 1.29
Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum (2008) 1.26
Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum (2006) 1.24
Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam Study. Ann Epidemiol (1996) 1.22
Expert review on coronary calcium. Vasc Health Risk Manag (2008) 1.22
Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J (2007) 1.21
Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol (2006) 1.20
Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol (2009) 1.13
Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) (2003) 1.11
The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) (2009) 1.11
Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension (2009) 1.10
Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol (2008) 1.09
Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol (2009) 1.07
Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev (2009) 1.06
Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis (2008) 1.05
Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev (2008) 1.05
Arterial functions: how to interpret the complex physiology. Nephrol Dial Transplant (2010) 1.04
Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol (2009) 1.04
Relationship between brachial flow-mediated dilation and carotid intima-media thickness in an elderly cohort: the Cardiovascular Health Study. Atherosclerosis (2007) 1.03
Endothelial dysfunction precedes atherosclerosis in systemic sclerosis--relevance for prevention of vascular complications. Rheumatology (Oxford) (2007) 1.02
Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol (2009) 1.00
Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis. Isr Med Assoc J (2011) 0.99
Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann N Y Acad Sci (2007) 0.99
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA (2011) 2.73
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis (2007) 2.67
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55
Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis (2012) 2.54
Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum (2009) 2.49
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum (2004) 2.32
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28
Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum (2008) 2.21
Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14
The Lancet against Israel. Isr Med Assoc J (2013) 2.03
Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02
Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: prevalence and clinical value. Autoimmunity (2008) 1.90
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis (2010) 1.81
The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79
Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum (2008) 1.78
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78
Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum (2007) 1.78
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) (2003) 1.75
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum (2004) 1.75
Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol (2008) 1.75
Evaluation of tear osmolarity in non-Sjögren and Sjögren syndrome dry eye patients with the TearLab system. Cornea (2012) 1.74
Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69
Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68
Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67
Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol (2006) 1.66
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 1.64
Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci (2005) 1.63
The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum (2011) 1.63
Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum (2006) 1.62
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62
Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62
The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57
The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (2009) 1.57
The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 1.54
Gender and autoimmunity. Autoimmun Rev (2006) 1.54
Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis (2013) 1.54
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Inflammatory bowel disease: adverse effect of isotretinoin. Isr Med Assoc J (2009) 1.51
Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48
Association of systemic and thyroid autoimmune diseases. Clin Rheumatol (2005) 1.48
Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol (2006) 1.46
Controversies on the use of corticosteroid therapy in children with Henoch-Schönlein purpura. Semin Arthritis Rheum (2005) 1.44
Thymoma and autoimmunity. Cell Mol Immunol (2011) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet (2008) 1.43
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43
Predictors of positive temporal artery biopsy in patients with giant cell arteritis and polymyalgia rheumatica (comment on the article by Marí et al.). Eur J Intern Med (2009) 1.42
Intelligent nutrition: health-promoting mechanisms of probiotics. Isr Med Assoc J (2003) 1.42
Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev (2009) 1.40
Different type of carotid arterial wall remodeling in rheumatoid arthritis compared with healthy subjects: a case-control study. J Rheumatol (2012) 1.40
Successful Etanercept Treatment for Primary Biliary Cirrhosis Associated with Rheumatoid Arthritis. Isr Med Assoc J (2015) 1.39
Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci (2005) 1.39
Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39
Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. J Autoimmun (2009) 1.38
Hippocrates' Oath is challenged. Isr Med Assoc J (2009) 1.38
Infections and SLE. Autoimmunity (2005) 1.38
CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36
Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36
Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36
Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity (2005) 1.36
HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med (2003) 1.36
Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006) 1.35
Parotitis as the presenting symptom of Wegener's granulomatosis: case report and meta-analysis. Isr Med Assoc J (2013) 1.35
High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum (2007) 1.31
What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31
Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol (2013) 1.31
Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum (2010) 1.31
Infections and autoimmunity--friends or foes? Trends Immunol (2009) 1.31
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther (2012) 1.29
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29